Cell and Gene Therapy in Parkinson's Disease Pipeline: 18+ Innovators Shaping the Future of Innovative Treatments | DelveInsight

The cell and gene therapy landscape in Parkinson's disease is undergoing a transformative evolution, led by pioneers like Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, Prevail Therapeutics, and S.Biomedics. These innovators are harnessing regenerative precision and stem cell platforms to target disease progression at its root-offering renewed hope for long-term relief and functional restoration.

DelveInsight's "Cell and Gene Therapy in Parkinson's Disease Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the cell and gene therapy in Parkinson's disease market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging cell and gene therapy in Parkinson's disease drugs, the cell and gene therapy in Parkinson's disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Cell and Gene Therapy in Parkinson's Disease Pipeline Report
• DelveInsight's cell and gene therapy in Parkinson's disease pipeline analysis depicts a robust space with 18+ active players working to develop 20+ pipeline drugs for cell and gene therapy in Parkinson's disease treatment.
• The leading cell and gene therapy in Parkinson's disease companies include Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, Prevail Therapeutics, S.Biomedics, MeiraGTx, Asklepios BioPharmaceutical, Hope Biosciences, and others are evaluating their lead assets to improve the cell and gene therapy in Parkinson's disease treatment landscape.
• Key cell and gene therapy in Parkinson's disease pipeline therapies in various stages of development include CT1 DAP001/DSP 1083, BRT-DA01, ANPD 001, LY3884961, A9-DPC, NLX P101, AB-1005, HB-adMSCs, and others.
• In March 2025, MedRhythms announced that MR-005, its neurorehabilitation system designed to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), has been classified as a Class II, Rx-only medical device by the U.S. Food and Drug Administration (FDA). The system will be marketed under the brand name Movive.
• In March 2025, Medtronic plc, a global leader in healthcare technology, announced the FDA approval of BrainSenseTM Adaptive deep brain stimulation (aDBS) and BrainSenseTM Electrode Identifier (EI). While there is no cure for debilitating neurological conditions like Parkinson's, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson's and other neurological disorders for over 30 years.
• In Feb 2025, Medtronic received FDA approval for its BrainSenseTM Adaptive deep brain stimulation (aDBS) for Parkinson's disease, marking a significant advancement in neuromodulation therapy.
• In February 2025, AB-1005, AskBio's investigational gene therapy for Parkinson's disease, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA to accelerate its development and review for treating serious or life-threatening conditions.
• In February 2025, the FDA approved CTEXLI (chenodiol) for treating cerebrotendinous xanthomatosis (CTX) in adults, making it the first FDA-approved drug for this rare lipid storage disease.
• In February 2025, Newronika received FDA Investigational Device Exemption (IDE) clearance to begin a pivotal U.S. clinical trial. The trial will assess the safety and efficacy of its adaptive deep brain stimulation system for patients with movement disorders, including Parkinson's disease.
• In February 2025, Supernus Pharmaceuticals, Inc. announced that the FDA approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for treating motor fluctuations in adults with advanced Parkinson's disease.

Request a sample and discover the recent breakthroughs happening in the cell and gene therapy in Parkinson's disease pipeline landscape @ https://www.delveinsight.com/report-store/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cell and Gene Therapy in Parkinson's Disease Overview
Cell and gene therapies are emerging as promising approaches to address the underlying pathology of Parkinson's disease (PD), a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons. Cell therapy strategies aim to replace these lost neurons using stem cell-derived dopaminergic cells or patient-specific induced pluripotent stem cells (iPSCs). Several companies, including BlueRock Therapeutics, Aspen Neuroscience, and S.Biomedics, are advancing clinical-stage programs that seek to restore motor function and slow disease progression through neuronal replacement.

Gene therapy, on the other hand, targets the molecular drivers of PD. By delivering therapeutic genes directly into the brain, these treatments can boost dopamine production, improve enzyme activity, or protect neurons from degeneration. Notable gene therapy approaches include AADC gene transfer and neuroprotective factor delivery. Companies such as Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, and Prevail Therapeutics are actively developing these technologies, offering hope for more durable, disease-modifying interventions in PD.

Find out more about cell and gene therapy in Parkinson's disease medication @ https://www.delveinsight.com/report-store/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cell and Gene Therapy in Parkinson's Disease Treatment Analysis: Drug Profile
AB-1005: Asklepios BioPharmaceutical
AB-1005 is an investigational gene therapy utilizing an adeno-associated viral vector serotype 2 (AAV2) to deliver the human glial cell line-derived neurotrophic factor (GDNF) transgene. This allows for stable, localized expression of GDNF in the brain following direct neurosurgical injection with MRI-monitored convection-enhanced delivery. GDNF is a member of the transforming growth factor-β superfamily and has shown promise in promoting the survival and differentiation of dopaminergic neurons in midbrain cultures. It has been investigated as a potential neurorestorative treatment for diseases like Parkinson's, characterized by the degeneration of dopaminergic neurons. AB-1005 is currently in Phase II clinical trials for the treatment of Parkinson's disease.

HB-adMSCs: Hope Biosciences
Hope Biosciences' Adipose-Derived Mesenchymal Stem Cells (HB-adMSCs) are in clinical development for treating Parkinson's disease (PD). While the precise mechanism of action remains unclear, mesenchymal stem cells are generally believed to exert their therapeutic effects through a variety of mechanisms, including tissue repair and modulation of inflammation. Currently, HB-adMSCs are undergoing Phase II clinical trials for the treatment of PD.

Key Cell and Gene Therapy in Parkinson's Disease Therapies and Companies
• AB-1005 : Asklepios BioPharmaceutical
• HB-adMSCs: Hope Biosciences
• ANPD 001: Aspen Neuroscience
• BRT-DA01: BlueRock Therapeutics
• AAV-GAD: MeiraGTx
• HB-adMSCs: Hope Biosciences
• PR001 (LY3884961): Prevail Therapeutics (Eli Lilly)

Learn more about the novel and emerging cell and gene therapy in Parkinson's disease pipeline therapies @ https://www.delveinsight.com/report-store/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cell and Gene Therapy in Parkinson's Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Cell and Gene Therapy in Parkinson's Disease Pipeline Report
• Coverage: Global
• Key Cell and Gene Therapy in Parkinson's Disease Companies: Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, Prevail Therapeutics, S.Biomedics, MeiraGTx, Asklepios BioPharmaceutical, Hope Biosciences, and others.
• Key Cell and Gene Therapy in Parkinson's Disease Pipeline Therapies: CT1 DAP001/DSP 1083, BRT-DA01, ANPD 001, LY3884961, A9-DPC, NLX P101, AB-1005, HB-adMSCs, and others.

Dive deep into rich insights for drugs used for cell and gene therapy in Parkinson's disease treatment; visit @ https://www.delveinsight.com/report-store/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cell and Gene Therapy in Parkinson's Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cell and Gene Therapy in Parkinson's Disease Pipeline Therapeutics
6. Cell and Gene Therapy in Parkinson's Disease Pipeline: Late-Stage Products (Phase III)
7. Cell and Gene Therapy in Parkinson's Disease Pipeline: Mid-Stage Products (Phase II)
8. Cell and Gene Therapy in Parkinson's Disease Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. Through our subscription-based platform, PharmDelve, you can get hassle-free access to all the healthcare and pharmaceutical market research reports.

This release was published on openPR.